Company Profile

Ariadne Diagnostics LLC (AKA: Ariadne-Dx)
Profile last edited on: 9/17/19      CAGE:       UEI:

Business Identifier: Companion diagnostic tests in the areas of metastatic colorectal cancer and neurodegenerative/neuromuscular diseases based on proprietary panels of biomarkers.
Year Founded
2011
First Award
2014
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9430 Key West Avenue Suite 115
Rockville, MD 20850
   (240) 345-1071
   info@ariadne-dx.com
   www.ariadne-dx.com
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Ariadne Diagnostics LLC (Ariadne-Dx) is a start-up diagnostic discovery and development company having licensed certain rights to discoveries and intellectual property with regard to biomarker panels for mCRC and neurodegenerative / neuromuscular diseases from Ariadne Genomics. Over the last decade that firm has designed and developed bioinformatics software and algorithms for biomedical research. Ariadne-Dx couples this vast experience in bioinformatics with expertise in biomarker discovery and clinical assay development.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $242,984
Project Title: An Assay to Measure Surrogate Biomarkers for DMD

Key People / Management

  Ilya Mazo -- Founder Acting Chief Executive Officer

  Nikolai Daraselia -- Founder

  Michael S Lebowitz -- Founder, Vice President Of Research & Development

  Elena Schwartz -- Founder, Chief Scientific Officer

  Anton Yuryev -- Founder

Company News

There are no news available.